The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Cg Oncology Inc (NASDAQ: CGON) closed at $25.29 down -6.12% from its previous closing price of $26.94. In other words, the price has decreased by -$6.12 from its previous closing price. On the day, 0.82 million shares were traded. CGON stock price reached its highest trading level at $27.15 during the session, while it also had its lowest trading level at $25.2027.
Ratios:
For a deeper understanding of Cg Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 30.97 and its Current Ratio is at 30.97. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 02, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $41.
On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $23.Scotiabank initiated its Sector Perform rating on April 16, 2025, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 17 ’25 when POST LEONARD E sold 2,000 shares for $28.00 per share. The transaction valued at 56,000 led to the insider holds 0 shares of the business.
LEONARD E POST bought 2,000 shares of CGON for $52,160 on Jul 17 ’25. On May 21 ’25, another insider, POST LEONARD E, who serves as the Director of the company, sold 1,000 shares for $28.00 each. As a result, the insider received 28,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 1927737856 and an Enterprise Value of 1240340096. For the stock, the TTM Price-to-Sale (P/S) ratio is 2920.82 while its Price-to-Book (P/B) ratio in mrq is 2.74. Its current Enterprise Value per Revenue stands at 1873.625 whereas that against EBITDA is -9.232.
Stock Price History:
The Beta on a monthly basis for CGON is 0.89, which has changed by -0.23916966 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $40.47, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is -3.84%, while the 200-Day Moving Average is calculated to be -10.08%.
Shares Statistics:
For the past three months, CGON has traded an average of 1.01M shares per day and 892190 over the past ten days. A total of 76.22M shares are outstanding, with a floating share count of 44.88M. Insiders hold about 41.12% of the company’s shares, while institutions hold 68.15% stake in the company. Shares short for CGON as of 1752537600 were 10782077 with a Short Ratio of 10.64, compared to 1749772800 on 11077034. Therefore, it implies a Short% of Shares Outstanding of 10782077 and a Short% of Float of 14.979999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.39 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.57 and -$2.07 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.79, with 8.0 analysts recommending between -$0.84 and -$3.58.
